Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients

2007/06/01 by Nicole Suciu-Foca, Nicole Suciu‐Foca, Nikki Feirt +29 · 26 citations
Immunology and Microbiology · Medicine · #Biochemistry #Biology #Cancer #Cancer research #Cell #Immune Cell Function and Interaction #Immune system #Immunology #Internal medicine #Medicine #Monoclonal and Polyclonal Antibodies Research #T cell #T-cell and B-cell Immunology

paper · pdf · doi:10.4049/jimmunol.178.11.7432

openalex publication_date 2007/06/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Abstract

Attempts to enhance patients' immune responses to malignancies have been largely unsuccessful. We now describe an immune-escape mechanism mediated by the inhibitory receptor Ig-like transcript 3 (ILT3) that may be responsible for such failures. Using a humanized SCID mouse model, we demonstrate that soluble and membrane ILT3 induce CD8(+) T suppressor cells and prevent rejection of allogeneic tumor transplants. Furthermore, we found that patients with melanoma, and carcinomas of the colon, rectum, and pancreas produce the soluble ILT3 protein, which induces the differentiation of CD8(+) T suppressor cells and impairs T cell responses in MLC. These responses are restored by anti-ILT3 mAb or by depletion of soluble ILT3 from the serum. Immunohistochemical staining of biopsies from the tumors and metastatic lymph nodes suggests that CD68(+) tumor-associated macrophages represent the major source of soluble ILT3. Alternative splicing, resulting in the loss of the ILT3 transmembrane domain, may contribute to the release of ILT3 in the circulation. These data suggest that ILT3 depletion or blockade is crucial to the success of immunotherapy in cancer. In contrast, the inhibitory activity of soluble ILT3 on T cell alloreactivity in vitro and in vivo suggests the potential usefulness of rILT3 for immunosuppressive treatment of allograft recipients or patients with autoimmune diseases.

Cited by

• LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy
• Regulation of T-cell immunity by leucocyte immunoglobulin-like receptors: innate immune receptors for self on antigen-presenting cells. [europepmc]
• Escaping from rejection. [europepmc]
• Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. [europepmc]
• Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients. [europepmc]
• Compartment-specific immunity in the human gut: properties and functions of dendritic cells in the colon versus the ileum. [europepmc]
• Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. [europepmc]
• Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. [europepmc]
• Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. [europepmc]
• Molecular and Cellular Characterization of Human CD8 T Suppressor Cells. [europepmc]
• LILRB receptor-mediated regulation of myeloid cell maturation and function. [europepmc]
• LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. [europepmc]
• Phagocytosis checkpoints as new targets for cancer immunotherapy. [europepmc]
• LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. [europepmc]
• LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. [europepmc]
• Leukocyte Immunoglobulin-Like Receptors (LILRs) on Human Neutrophils: Modulators of Infection and Immunity. [europepmc]
• LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia. [europepmc]
• Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer. [europepmc]
• LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. [europepmc]
• The immune landscape of common CNS malignancies: implications for immunotherapy. [europepmc]
• Leukocyte Immunoglobulin-Like Receptors in Regulating the Immune Response in Infectious Diseases: A Window of Opportunity to Pathogen Persistence and a Sound Target in Therapeutics. [europepmc]
• Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy. [europepmc]
• Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. [europepmc]
• LILRB4, an immune checkpoint on myeloid cells. [europepmc]
• Human leukocyte immunoglobulin-like receptors in health and disease. [europepmc]
• LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development. [europepmc]

Related

• Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells
• Viewing Siglecs through the lens of tumor immunology
• The enigmatic function of IgD: some answers at last
• Mucosal‐Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets
• CD103+CD56+ ILCs Are Associated with an Altered CD8+ T-cell Profile within the Tumor Microenvironment